Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Lonza Group

              • Deals

              Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

              SWITZERLAND Switzerland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Kodiak, Lonza Sign Long-Term Manufacturing Contract

              Contact the Supplier

              Lead Product(s): KSI-301

              Therapeutic Area: Ophthalmology Product Name: KSI-301

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kodiak Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 27, 2020

              Details:

              Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.

              PharmaCompass__DigitalAd